ARTICLE | Emerging Company Profile
Lumen growing lean, green biologics with $16M series B and Gates funding
Having wrangled spirulina into making oral biologics, Lumen aims for low cost and high volume
September 4, 2020 6:28 PM UTC
Having turned photosynthetic bacteria into protein production machines, Lumen believes it has cracked the code to making cheap, oral biologics for widespread diseases in the Western and developing worlds.
The company’s $16 million series B round, announced Tuesday, was led by new investor WestRiver Management and returning investor Bioeconomy Capital, and brings its total funding to $68M, including a $20 million series A round and non-dilutive funding from the Bill & Melinda Gates Foundation. ...